Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).

doi:10.3390/ijms252111646

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).

International journal of molecular sciences - 30 Oct 2024

Oliva Esther Natalie, Cuzzola Maria, Porta Matteo Della, Candoni Anna, Salutari Prassede, Palumbo Giuseppe A, Reda Gianluigi, Iannì Giuseppe, Zampini Matteo, D'Amico Saverio, Tripepi Giovanni, Capelli Debora, Alati Caterina, Cannatà Maria Concetta, Niscola Pasquale, Serio Bianca, Barillà Santina, Musto Pellegrino, Vigna Ernesto, Melillo Lorella Maria Antonia, Tripepi Rocco, Zannier Maria Elena, Nannya Yasuhito, Ogawa Seishi, Mammì Corrado

Abstract excerpt

The achievement of complete remission (CR) is crucial for acute myeloid leukemia (AML) patients undertaking curative therapy, but relapse often occurs within months, highlighting the need for strategies to prolong disease-free survival (DFS). Our phase III study compared the efficacy and safety of azacitidine (AZA) to best supportive care (BSC) in elderly AML patients who achieved CR following intensive induction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to Dioxygenases

Share to DNA (Cytosine-5-)-Methyltransferases

Share to DNA Methyltransferase 3A

Share to Nucleophosmin

Share to Remission Induction

Share to Translational Research, Biomedical

Source

Open in PubMed Open full text

Identifiers

PMID: 39519198
DOI: 10.3390/ijms252111646
PMCID: PMC11545844

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).PMID 39519198Read ↗

Translational Research on Azacitidine Post- Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2)Semantic proximity Read ↗

Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia.Semantic proximity Read ↗

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.Semantic proximity Read ↗

Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia.Semantic proximity Read ↗

The clinical features and outcomes of elderly patients with acute myeloid leukemia: a real word research.Semantic proximity Read ↗

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional careSemantic proximity Read ↗

Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia.Semantic proximity Read ↗

A precision medicine classification for treatment of acute myeloid leukemia in older patients.Semantic proximity Read ↗

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionSemantic proximity Read ↗

Genomics of Acute Myeloid Leukemia at Diagnosis and RemissionSemantic proximity Read ↗

[Comparision of Mutational Spectrum between Elderly and Young Adults with Acute Myeloid Leukemia Based on Next Generation Sequencing].Semantic proximity Read ↗

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.